Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 2
1976 1
1977 2
1979 1
1980 4
1981 4
1982 2
1983 1
1984 3
1985 4
1986 2
1987 1
1988 4
1989 1
1990 5
1991 3
1992 3
1993 1
1994 1
1998 1
2002 2
2003 1
2004 2
2005 1
2008 1
2015 1
2016 1
2019 1
2020 2
2021 1
2022 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Intrapatient Randomization to Study Strut Coverage in Polymer-Free Versus Biodegradable-Polymer Sirolimus-Eluting Stent Implantations.
Otaegui I, Pérez de Prado A, Massotti M, López-Benito M, Sabaté M, Martí G, Bellera N, Serra B, García Del Blanco B, Ferreira González I. Otaegui I, et al. Among authors: massotti m. JACC Cardiovasc Interv. 2020 Apr 13;13(7):899-900. doi: 10.1016/j.jcin.2019.11.020. JACC Cardiovasc Interv. 2020. PMID: 32273102 Free article. Clinical Trial. No abstract available.
Can an ultrathin strut stent design and a polymer free, proendothelializing probucol matrix coating improve early strut healing? The FRIENDLY-OCT trial. An intra-patient randomized study with OCT, evaluating early strut coverage of a novel probucol coated polymer-free and ultra-thin strut sirolimus-eluting stent compared to a biodegradable polymer sirolimus-eluting stent.
Otaegui Irurueta I, González Sucarrats S, Barrón Molina JL, Pérez de Prado A, Massotti M, Carmona Ramírez MÁ, Martí G, Bellera N, Serra B, Serra V, Domingo E, López-Benito M, Sabaté M, Ferreira González I, García Del Blanco B. Otaegui Irurueta I, et al. Among authors: massotti m. Int J Cardiol. 2022 Aug 1;360:13-20. doi: 10.1016/j.ijcard.2022.04.043. Epub 2022 Apr 25. Int J Cardiol. 2022. PMID: 35472561 Clinical Trial.
GABA receptors as supramolecular units.
Mazzari S, Massotti M, Guidotti A, Costa E. Mazzari S, et al. Among authors: massotti m. Adv Biochem Psychopharmacol. 1981;26:1-8. Adv Biochem Psychopharmacol. 1981. PMID: 6257062 Review. No abstract available.
The neuroscience of drug addiction: Rome built in a day.
Pulvirenti L, Massotti M. Pulvirenti L, et al. Among authors: massotti m. Trends Pharmacol Sci. 2002 Dec;23(12):543-4. doi: 10.1016/s0165-6147(02)02144-2. Trends Pharmacol Sci. 2002. PMID: 12457766
Differences in 30-day complications and 1-year mortality by sex in patients with a first STEMI managed by the Codi IAM network between 2010 and 2016.
Tizón-Marcos H, Vaquerizo B, Marrugat J, Ariza A, Carrillo X, Muñoz JF, Cárdenas M, García-Picart J, Rojas SG, Tomás-Querol C, Massotti M, Lidón RM, Jiménez J, Martí-Almor J, Farré N, Pérez-Fernández S, Curós A, Mauri Ferré J. Tizón-Marcos H, et al. Among authors: massotti m. Rev Esp Cardiol (Engl Ed). 2021 Aug;74(8):674-681. doi: 10.1016/j.rec.2020.06.002. Epub 2020 Jul 11. Rev Esp Cardiol (Engl Ed). 2021. PMID: 32660910 English, Spanish.
59 results